Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Income from Continuing Operations (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Income from Continuing Operations for 6 consecutive years, with 124968000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 36.31% to 124968000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 256324000.0 through Dec 2025, up 23.41% year-over-year, with the annual reading at 256324000.0 for FY2025, 23.41% up from the prior year.
  • Income from Continuing Operations hit 124968000.0 in Q4 2025 for Lyell Immunopharma, down from 33987000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 11331000.0 in Q4 2022 to a low of 196227000.0 in Q4 2024.
  • Historically, Income from Continuing Operations has averaged 60409100.0 across 5 years, with a median of 52427500.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 76.0% in 2022 and later tumbled 362.66% in 2023.
  • Year by year, Income from Continuing Operations stood at 47215000.0 in 2021, then surged by 76.0% to 11331000.0 in 2022, then plummeted by 362.66% to 52424000.0 in 2023, then tumbled by 274.31% to 196227000.0 in 2024, then surged by 36.31% to 124968000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for LYEL at 124968000.0 in Q4 2025, 33987000.0 in Q3 2025, and 43864000.0 in Q2 2025.